AFATINIB IN THE TREATMENT OF METASTATIC AND LOCALLY ADVANCED LUNG ADENOCARCINOMA WITH EGFR MUTATIONS: NEW SIDES STUDIED POSSIBILITIES
A reasonable strategy for drug therapy of non-small-cell lung cancer (NSCLC) with activating mutations of EGFR is the use of tyrosine kinase inhibitors (TKI) in front-line therapy, providing a two-fold increase in life expectancy for patients with metastatic or locally advanced form of the disease....
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2017-11-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/2166 |